Simplicity Solutions LLC Lowers Stock Position in Genmab A/S (NASDAQ:GMAB)

Simplicity Solutions LLC lessened its stake in shares of Genmab A/S (NASDAQ:GMAB) by 7.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,305 shares of the company’s stock after selling 1,669 shares during the quarter. Simplicity Solutions LLC’s holdings in Genmab A/S were worth $710,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. First Manhattan Co. acquired a new stake in Genmab A/S in the fourth quarter valued at approximately $26,000. Headlands Technologies LLC acquired a new stake in Genmab A/S in the third quarter valued at approximately $27,000. Pinnacle Bancorp Inc. raised its holdings in Genmab A/S by 315.8% in the fourth quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock valued at $27,000 after acquiring an additional 638 shares in the last quarter. NBC Securities Inc. acquired a new stake in Genmab A/S in the third quarter valued at approximately $37,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Genmab A/S by 86.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company’s stock valued at $38,000 after acquiring an additional 498 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Trading Down 3.1 %

Shares of GMAB opened at $28.53 on Thursday. The firm has a market cap of $18.86 billion, a PE ratio of 29.72, a price-to-earnings-growth ratio of 2.12 and a beta of 0.99. The company’s 50 day simple moving average is $29.35 and its 200-day simple moving average is $30.35. Genmab A/S has a 12-month low of $26.32 and a 12-month high of $42.72.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.02. The business had revenue of $675.29 million for the quarter, compared to analyst estimates of $678.14 million. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. As a group, equities research analysts forecast that Genmab A/S will post 1.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on GMAB. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Thursday, April 4th. BMO Capital Markets raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and raised their target price for the company from $46.00 to $48.00 in a report on Friday, February 23rd. Citigroup cut shares of Genmab A/S from a “neutral” rating to a “sell” rating in a report on Monday, January 22nd. Truist Financial reissued a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Tuesday, March 26th. Finally, Morgan Stanley reissued an “underweight” rating on shares of Genmab A/S in a report on Tuesday, March 26th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $48.50.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.